<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Malignancy after solid organ transplantation</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Malignancy after solid organ transplantation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Malignancy after solid organ transplantation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel C Brennan, MD, FACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Rodeheffer, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard F Ambinder, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John Vella, MD, FACP, FRCP, FASN, FAST</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 03, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H723416171"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>In recipients of a solid organ transplant, the chronic use of immunosuppressive agents to prevent allograft rejection increases the long-term risk of malignancy compared with that of the general population.</p><p>This topic will review the general issue of malignancy following solid organ transplantation. Malignancy following hematopoietic cell transplantation, skin cancer following solid organ transplantation, and lymphoproliferative disorders following solid organ transplantation are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3558.html" rel="external">"Secondary cancers after hematopoietic cell transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16332.html" rel="external">"Epidemiology and risk factors for skin cancer in solid organ transplant recipients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16339.html" rel="external">"Prevention and management of skin cancer in solid organ transplant recipients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/83230.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7335.html" rel="external">"Treatment and prevention of post-transplant lymphoproliferative disorders"</a>.)</p><p></p><p class="headingAnchor" id="H2685618392"><span class="h1">EPIDEMIOLOGY AND RISK FACTORS</span></p><p class="headingAnchor" id="H904958577"><span class="h2">Incidence</span><span class="headingEndMark"> — </span>Solid organ transplantation is associated with an increased risk of a wide range of cancers [<a href="#rid1">1-8</a>]. The most extensive data come from a large cohort study that analyzed the frequency of malignancy in over 175,000 solid organ transplant recipients during the period 1987 to 2008 [<a href="#rid1">1</a>]. The most common organs transplanted included kidney, liver, heart, and lung (in 58, 22, 10, and 4 percent of cases, respectively). Overall, malignancy was identified in 10,656 cases, which correlated with a standardized incidence ratio (SIR) of 2.1 (95% CI 2.06-2.14) compared with the general population and an excess absolute risk of 719 cases per 100,000 person years.</p><p>A significantly increased risk of malignancy was associated with more than 30 different primary sites. Tumor sites with a fivefold or greater increase, compared with the general population, included the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Kaposi sarcoma (KS; SIR 61.5)</p><p class="bulletIndent1"><span class="glyph">●</span>Skin (nonmelanoma, nonepithelial; SIR 13.9)</p><p class="bulletIndent1"><span class="glyph">●</span>Non-Hodgkin lymphoma (SIR 7.5)</p><p class="bulletIndent1"><span class="glyph">●</span>Liver (SIR 11.6)</p><p class="bulletIndent1"><span class="glyph">●</span>Anus (SIR 5.8)</p><p class="bulletIndent1"><span class="glyph">●</span>Vulva (SIR 7.6)</p><p class="bulletIndent1"><span class="glyph">●</span>Lip (SIR 16.8)</p><p></p><p>Of note, these malignancies are associated with viral infections. (See <a class="local">'Coexisting viral infection'</a> below.)</p><p>Other common malignancies with an increased risk included the following: </p><p class="bulletIndent1"><span class="glyph">●</span>Kidney (SIR 4.7)</p><p class="bulletIndent1"><span class="glyph">●</span>Hodgkin lymphoma (SIR 3.6)</p><p class="bulletIndent1"><span class="glyph">●</span>Melanoma (SIR 2.4)</p><p class="bulletIndent1"><span class="glyph">●</span>Lung (SIR 2.0)</p><p class="bulletIndent1"><span class="glyph">●</span>Pancreas (SIR 1.5)</p><p class="bulletIndent1"><span class="glyph">●</span>Colon and rectum (SIR 1.2)</p><p></p><p>Other primary malignancies that were increased, but to a lesser extent, included stomach, oral cavity, larynx, pharynx, vulva, penis, thyroid, urinary bladder, esophagus, salivary glands, soft tissue sarcomas, small intestine, testis, biliary tract, acute myeloid leukemia, plasma cell neoplasms, and chronic myeloid leukemia.</p><p>By contrast, the incidence of breast cancer was decreased (SIR 0.85), as was the risk of prostate cancer (SIR 0.92).</p><p>This analysis also found that the incidence of specific malignancies varied depending upon the organ transplanted [<a href="#rid1">1</a>]. As an example, the frequency of non-Hodgkin lymphoma was approximately twofold greater in recipients of lung transplants compared with those who received a kidney, liver, or heart transplant. Conversely, there was an approximately threefold increase in lung cancer among lung transplant recipients, and the frequency of liver and kidney cancer was increased in liver and kidney transplant recipients, respectively.</p><p>Similar patterns of increased incidence have been observed in other studies of both adults and children [<a href="#rid2">2-8</a>].</p><p class="headingAnchor" id="H1586023808"><span class="h2">Risk factors for malignancy</span><span class="headingEndMark"> — </span>Several factors have been linked to the increased incidence of secondary malignancies among transplant recipients, including sun exposure; type, extent, and duration of immunosuppression; and concomitant viral infection. In rare cases, malignancy has been transplanted from the donor.</p><p>The risk factors associated with an increased risk of skin cancer and posttransplant lymphoproliferative disorders (PTLDs) are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16332.html" rel="external">"Epidemiology and risk factors for skin cancer in solid organ transplant recipients", section on 'Risk factors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/83230.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders", section on 'Risk factors'</a>.)</p><p></p><p class="headingAnchor" id="H2188700926"><span class="h3">Immunosuppression</span><span class="headingEndMark"> — </span>The overall level of immunosuppression appears to be the principal factor that increases the risk of posttransplant malignancy [<a href="#rid9">9</a>]. The relationship between an increased level of immunosuppression and the likelihood of malignancy can be illustrated by the following data:</p><p class="bulletIndent1"><span class="glyph">●</span>In a study of over 50,000 kidney and heart transplants from centers in Europe and North America, the incidence of PTLD was highest in the first year, the time of most intense immunosuppression, and fell by approximately 80 percent thereafter  (<a class="graphic graphic_figure graphicRef50807" href="/z/d/graphic/50807.html" rel="external">figure 1</a>) [<a href="#rid10">10</a>]. The incidence was significantly greater in heart transplant recipients, a finding consistent with the greater degree of immunosuppression in these patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Episodes of graft rejection in the first year after transplantation increase the likelihood of developing a secondary malignancy, possibly because of the greater level of immunosuppression that is required to treat rejection [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In one trial, 231 kidney allograft recipients were randomly assigned after 12 months of standard immunosuppressive therapy to receive <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> doses adjusted to yield trough blood concentrations between 75 to 125 ng/mL (low-dose group) or doses that yielded trough concentrations between 150 to 250 ng/mL (normal-dose group) [<a href="#rid12">12</a>]. At a median of 66 months, patients receiving the low-dose cyclosporine regimen had a lower incidence of all secondary cancers (23 versus 37 cancers), particularly skin cancers (17 versus 26 cancers).</p><p></p><p>The risk of malignancy appears to vary depending upon the agents used for immunosuppression:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibody therapy </strong>– Antibody therapy directed against T lymphocytes (as with OKT3 or antilymphocyte serum) specifically predisposes to PTLD induced by Epstein-Barr virus (EBV). By contrast, antibody therapy targeting B lymphocytes (as with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>) may reduce the incidence of lymphoproliferative disorders and is regarded by many as appropriate first-line therapy for these disorders. This is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/83230.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders", section on 'Degree of immunosuppression'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Calcineurin inhibitors </strong>– Limited evidence from animal models suggests that <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> may promote cancer progression, principally via the production of transforming growth factor-beta (TGF-beta). In vitro, cyclosporine induces invasive behavior of nontransformed cells in association with striking morphologic changes; in addition, cyclosporine administration promotes tumor growth in immunodeficient animals [<a href="#rid13">13</a>]. Both the in vitro and in vivo changes were prevented by the administration of anti-TGF-beta antibodies.</p><p></p><p class="bulletIndent1">An increase in proangiogenic effect due to elevated expression of vascular endothelial growth factor has been reported with <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> [<a href="#rid14">14-16</a>]. Another notable cytokine with increased levels is interleukin-6, which may help EBV-induced B-cell growth [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1">Data from one series suggest that the use of <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> increases the risk of malignancy following kidney transplantation [<a href="#rid17">17</a>]. Tacrolimus appears to increase TGF-beta levels [<a href="#rid18">18</a>], an effect clearly associated with tumor growth with <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Azathioprine</strong><strong> </strong>– The use of <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> has been associated with malignancy posttransplantation, particularly an increased risk of cutaneous squamous cell carcinoma [<a href="#rid9">9</a>]. The mechanism of action is postulated via intercalation of DNA to be the inhibition of repair splicing and induction of codon misreads [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mycophenolate</strong><strong> mofetil</strong> – <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">Mycophenolate</a> mofetil impairs lymphocyte function by blocking purine biosynthesis via inhibition of the enzyme, inosine monophosphate dehydrogenase. Some malignancies, including some solid tumors, have dramatic elevations of this enzyme, suggesting that this agent may have some antiproliferative activity [<a href="#rid9">9,20</a>].</p><p></p><p class="bulletIndent1">Some population studies also suggest that the risk of developing a malignancy is not higher with <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil and may actually be associated with a decreased risk [<a href="#rid9">9,21,22</a>]. In a study using data from two large registries, there was a nonsignificant trend to a decreased risk with mycophenolate- versus non-mycophenolate-based therapy [<a href="#rid21">21</a>]. A principal mechanism of a lower malignancy risk with mycophenolate mofetil, to the degree that it occurs, may be due to the decreased incidence of acute rejection. This results in a reduced need for increased doses of immunosuppressive agents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sirolimus</strong><strong> </strong>– Some data suggest that <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>, an inhibitor of the mammalian (mechanistic) target of rapamycin (mTOR), suppresses the growth and proliferation of tumors in various animal models [<a href="#rid14">14,16,23</a>]. Possible mechanisms of actions include inhibition of p70 S6K (thereby decreasing cell proliferation), interleukin-10 (decreasing tumor cell Jak/STATs activity), and cyclins (blocking cell cycle activity). Lymphangiogenesis also appears to be impeded via impaired signaling of vascular endothelial growth factors A and C [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1">In humans, evidence also suggests that <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> may confer a decreased risk of malignancy compared with other immunosuppressive medications [<a href="#rid16">16,25-32</a>]. The best data are from a systematic review and meta-analysis of randomized trials that compared immunosuppressive regimens with and without sirolimus using patient-level data from kidney and kidney-pancreas transplant recipients [<a href="#rid30">30</a>]. Compared with controls, sirolimus was associated with a 40 percent decrease in the overall risk of malignancy and a 56 percent decrease in the risk of nonmelanoma skin cancer. This result was most striking among patients who converted to sirolimus from another immunosuppressive regimen with an overall decrease in malignancy risk (hazard ratio [HR] 0.34, 95% CI 0.28-0.41), nonmelanoma skin cancer (HR 0.32, 95% CI 0.24-0.42), and other cancers (HR 0.52, 95% CI 0.38-0.69). By contrast, analysis of de novo sirolimus trials revealed no difference in malignancy risk between sirolimus and controls. However, sirolimus was associated with an increased mortality risk (HR 1.43, 95% CI 1.21-1.71), driven by increased cardiovascular and infection-related deaths in the sirolimus group. Some studies have found a higher incidence of prostate cancer associated with sirolimus use among transplant recipients [<a href="#rid31">31,32</a>]. (See  <a class="medical medical_review" href="/z/d/html/16339.html" rel="external">"Prevention and management of skin cancer in solid organ transplant recipients", section on 'mTOR inhibitors'</a>.)</p><p></p><p class="headingAnchor" id="H1550489930"><span class="h3">Coexisting viral infection</span><span class="headingEndMark"> — </span>At least four viruses may be cocarcinogenic in transplanted patients: EBV, human herpesvirus 8 (HHV-8), human papillomavirus (HPV), and the Merkel cell polyomavirus (MCV).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epstein-Barr virus and lymphoma </strong>– Lymphomas are among the most common complications of transplantation; many are related to EBV infection. This topic is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/83230.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders", section on 'Pathogenesis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Human herpesvirus 8 and Kaposi sarcoma </strong>– The presence of HHV-8 in tumor tissue has been recognized in all forms of KS: classic KS, endemic KS, acquired immune deficiency syndrome (AIDS) KS, and posttransplant KS, with serologic evidence of infection also being common [<a href="#rid33">33,34</a>]. (See  <a class="medical medical_review" href="/z/d/html/8319.html" rel="external">"Human herpesvirus-8 infection"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A study of kidney transplant recipients from Saudi Arabia, in whom the incidence of KS is approximately 10-fold higher than in patients from Western countries, found a markedly higher incidence of specific anti-HHV-8 antibodies in patients with KS compared with those without it (92 versus 28 percent) [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a report of 400 consecutive kidney transplant recipients, 32 had antibodies to HHV-8 at the time of transplantation [<a href="#rid36">36</a>]. Three years after surgery, 28 percent of antibody-positive patients had developed KS compared with no cases in antibody-negative patients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There is convincing evidence of transmission of HHV-8 from the donor to kidney and cardiac transplant recipients [<a href="#rid37">37-40</a>]. Not only is the virus transmitted, but, in at least one series, the tumor cells are also commonly (five of eight) donor derived.</p><p></p><p class="bulletIndent1">HHV-8 infection is necessary but not sufficient for the development of KS. Transplanted-related immune dysfunction is an important contributing cofactor. Pretransplant antibody screening would appear to be useful for identifying high-risk patients; it is not routinely performed in the United States but may be performed in endemic areas [<a href="#rid41">41</a>]. If pursued, donor testing is warranted as well, particularly in areas with high seroprevalence.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Human papillomavirus and squamous skin cancers </strong>– The potential role of HPV infection in the pathogenesis of squamous cell skin cancers is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16332.html" rel="external">"Epidemiology and risk factors for skin cancer in solid organ transplant recipients", section on 'Risk factors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Merkel cell polyomavirus and Merkel cell carcinoma </strong>– MCV is believed to be a contributing factor to Merkel cell carcinoma. The data supporting this relationship are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7623.html" rel="external">"Pathogenesis, clinical features, and diagnosis of Merkel cell (neuroendocrine) carcinoma", section on 'Pathogenesis'</a>.)</p><p></p><p class="headingAnchor" id="H1846516320"><span class="h3">Donor transmission</span><span class="headingEndMark"> — </span>Unintended transmission of malignant cells from a donor is rare but may result in metastatic cancer in the immunosuppressed transplant recipient [<a href="#rid42">42-48</a>]. In a survey of a single kidney transplant center's experience, the risks of having a donor with an undetected malignancy and of transmitting the cancer were 1.3 and 0.2 percent, respectively [<a href="#rid44">44</a>].</p><p>This was also illustrated by a series from the Cincinnati Tumor Registry that included 22 patients who received donor hearts and/or lungs from patients who had a history of malignancy; malignant tumors subsequently developed in 45 percent of the recipients [<a href="#rid48">48</a>]. Almost all of these tumors were believed to have occurred because of the presence of occult malignant cells in the transplanted organ.</p><p>The risk of inadvertent transplantation of malignant cells appears to depend upon the type and extent of the donor's cancer. In the Cincinnati Tumor Registry report, although the numbers were small, the authors concluded that a history of renal cell cancer without capsular invasion appeared to be safe, but not if vascular invasion was present. No malignancy transmission was noted with central nervous system (CNS) tumors, with the exception of one medulloblastoma. By contrast, a history of melanoma or choriocarcinoma was associated with high rates of transmission, with early and almost universal death.</p><p>A variety of donor-transmitted malignancies have been documented including melanoma and cancers of the lung, breast, colon, rectum, and kidney, KS, and glioblastoma multiforme. In one review, malignancy developed in 78 of 142 (45 percent) patients who received a cadaver graft from a donor subsequently found to have a tumor. Metastatic disease occurred in 36, while complete remission occurred in 9 of the 20 patients treated with cessation of immunosuppression with or without graft nephrectomy. In comparison, transmission of nonmelanoma skin cancer and some CNS tumors appears to be rare, and the risk appears very low in donors with a past history of cancer but no evidence of current disease [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H415523931"><span class="h2">Cancer mortality</span><span class="headingEndMark"> — </span>Cancer is one of the leading causes of death among solid organ transplant recipients, accounting for 13 to 20 percent of deaths in various studies [<a href="#rid50">50-53</a>]. Overall cancer mortality is approximately 2.3- to 2.8-fold higher among solid organ transplant recipients compared with the general population, and mortality is increased for most individual cancer sites, particularly non-Hodgkin lymphoma, kidney cancer, melanoma, and, among liver recipients, liver cancer [<a href="#rid50">50-53</a>]. Most of this increased risk is driven by de novo malignancies. (See  <a class="medical medical_review" href="/z/d/html/7347.html" rel="external">"Kidney transplantation in adults: Patient survival after kidney transplantation", section on 'Causes of death'</a>.)</p><p class="headingAnchor" id="H743379138"><span class="h1">COMMON CANCER TYPES IN TRANSPLANT RECIPIENTS</span></p><p class="headingAnchor" id="H3733335059"><span class="h2">Skin cancers</span><span class="headingEndMark"> — </span>Skin cancers, especially squamous cell and basal cell carcinomas, but also melanoma, Merkel cell carcinoma, and Kaposi sarcoma (KS), are more common than in the nontransplant population. The issues surrounding these malignancies are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16332.html" rel="external">"Epidemiology and risk factors for skin cancer in solid organ transplant recipients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16339.html" rel="external">"Prevention and management of skin cancer in solid organ transplant recipients"</a>.)</p><p></p><p class="headingAnchor" id="H2249980"><span class="h2">Kaposi sarcoma</span><span class="headingEndMark"> — </span>Most cases of posttransplant KS occur in individuals of Mediterranean, Jewish, Arabic, Caribbean, or African descent [<a href="#rid54">54</a>]. This is a function of the geographic distribution of human herpesvirus 8 (HHV-8, also known as KS-associated herpesvirus). There is a male predilection (male to female ratio 3.3:1), and the average age at diagnosis is 43 years, younger than for patients with classic KS [<a href="#rid55">55,56</a>]. The average time to presentation is 13 to 21 months following transplantation [<a href="#rid57">57</a>]. (See <a class="local">'Coexisting viral infection'</a> above.)</p><p>The clinical presentation is similar to that of classic KS, manifested as angiomatous lesions predominantly affecting the legs and causing lymphedema. Although the incidence varies by population, approximately 90 percent of patients have cutaneous and/or mucosal lesions, while 10 percent have disease that is limited to the viscera [<a href="#rid58">58,59</a>]. For unclear reasons, visceral involvement is less common in patients with kidney as compared with liver or heart allografts (25 to 30 versus 50 percent). At least partly because of this, patients who develop KS after a liver or heart transplant have shorter survival than those who have undergone kidney transplantation [<a href="#rid58">58,60</a>].</p><p>KS may respond to reduction or discontinuation of the immunosuppressive regimen, and this should be the first therapeutic maneuver [<a href="#rid57">57</a>]. Among patients listed in the Cincinnati registry, for example, reduction in immunosuppressive therapy was associated with the disappearance of KS in 17 and 16 percent of patients with mucocutaneous disease and visceral involvement, respectively [<a href="#rid61">61,62</a>]. In addition, the substitution of <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> for <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> in a total of 17 kidney transplant recipients has been associated with complete regression of KS [<a href="#rid27">27,63</a>]. Given these results, converting to sirolimus from a calcineurin inhibitor in this setting may be reasonable if there are no contraindications for this strategy. (See <a class="local">'Reduction in immunosuppression'</a> below.)</p><p>Additional treatment options, which may be required for cases that do not regress spontaneously, are similar to those considered for patients without immunosuppression. (See  <a class="medical medical_review" href="/z/d/html/8034.html" rel="external">"AIDS-related Kaposi sarcoma: Staging and treatment"</a>.)</p><p class="headingAnchor" id="H2206512106"><span class="h2">Lymphoproliferative disorders</span><span class="headingEndMark"> — </span>The majority of malignant lymphoproliferative disorders occurring following solid organ transplantation are of B cell origin, most commonly non-Hodgkin lymphoma. T cell lymphoproliferative disorders have been described but are rare. These disorders are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/83230.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders"</a>.)</p><p class="headingAnchor" id="H4235394668"><span class="h2">Anogenital cancers</span><span class="headingEndMark"> — </span>Cancers involving the anogenital region (ie, anus, vulva, perianal region, penis, scrotum, or perineum) account for 2 to 3 percent of cancers in transplant recipients [<a href="#rid64">64-66</a>]. Lesions tend to be multiple and/or extensive, particularly in women, one-third of whom have concurrent cervical cancer. Clinically, these lesions often appear as pigmented papular lesions, but they may resemble genital warts.</p><p>Anogenital cancers present an average of 84 to 112 months following transplantation [<a href="#rid57">57</a>]. The latency is even longer among patients who received allografts as children, in whom the lesions often develop during adulthood (mean interval after transplantation was 142 months for carcinomas of the vulva and perineum in one series [<a href="#rid67">67</a>]).</p><p>In situ anogenital cancers can be treated with laser therapy, electrocautery, or topical <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a>. Topical <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">imiquimod</a>, which is available for the treatment of anogenital warts, has not been systematically studied in transplant recipients. Tapering the immunosuppressive regimen is beneficial and may lead to resolution of in situ carcinomas [<a href="#rid68">68</a>]. (See  <a class="medical medical_review" href="/z/d/html/8032.html" rel="external">"Anal squamous intraepithelial lesions: Epidemiology, clinical presentation, diagnosis, screening, prevention, and treatment", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/3235.html" rel="external">"Vulvar squamous intraepithelial lesions (vulvar intraepithelial neoplasia)", section on 'Treatment'</a>.)</p><p>Invasive tumors require wide local excision (eg, radical vulvectomy), with inguinal lymphadenectomy for tumors &gt;1 mm thick and adjuvant therapy in selected patients (see  <a class="medical medical_review" href="/z/d/html/3237.html" rel="external">"Vulvar cancer: Epidemiology, diagnosis, histopathology, and treatment"</a>). The management of anal margin and anal canal lesions is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2469.html" rel="external">"Clinical features and staging of anal cancer"</a>.)</p><p class="headingAnchor" id="H826396247"><span class="h2">Lung cancer</span><span class="headingEndMark"> — </span>The incidence of lung cancer has been noted to be particularly increased in recipients of heart and lung transplants, and this may be related to the high incidence of cigarette smoking leading to heart and lung disease [<a href="#rid69">69-72</a>]. However, the incidence also appears to be increased following kidney and liver transplants [<a href="#rid73">73</a>].</p><p>Lung transplants are frequently carried out in patients with chronic obstructive lung disease secondary to smoking. In this setting, the incidence of lung cancer is markedly increased and frequently arises in the residual native lung in recipients of a single-lung transplant [<a href="#rid74">74</a>]. As an example, in a series of 520 lung transplants conducted at a single institution over a 17-year period, 12 patients developed lung cancer, 11 of which occurred in the residual native lung [<a href="#rid72">72</a>].</p><p>The increased incidence of lung cancer compared with the general population is similar to that seen in patients infected with HIV and thus may be a reflection of the role of chronic, prolonged immunosuppression. (See  <a class="medical medical_review" href="/z/d/html/8036.html" rel="external">"HIV infection and malignancy: Management considerations", section on 'Lung cancer'</a>.)</p><p>The management of lung cancer in recipients of heart or lung transplants is generally similar to that in nontransplant patients with lung cancer. The use of immune checkpoint inhibitors should be avoided, if possible, given the potential increased risk of organ rejection with this class of agents. (See <a class="local">'Avoidance of immune checkpoint inhibitors'</a> below.)</p><p class="headingAnchor" id="H1768270898"><span class="h2">Liver cancer</span><span class="headingEndMark"> — </span>The risk of liver cancer is markedly higher in liver transplant recipients compared with the general population [<a href="#rid1">1</a>]. The vast majority of these cancers are diagnosed within the first six months after transplantation. However, the risk of liver cancer does not appear to be higher in other solid organ transplant recipients. A more detailed discussion of liver cancer following liver transplantation is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2490.html" rel="external">"Liver transplantation for hepatocellular carcinoma", section on 'Post-transplantation surveillance'</a> and  <a class="medical medical_review" href="/z/d/html/4589.html" rel="external">"Liver transplantation in adults: Long-term management of transplant recipients", section on 'Screening and prevention'</a>.)</p><p class="headingAnchor" id="H3751984290"><span class="h2">Kidney cancer</span><span class="headingEndMark"> — </span>In kidney transplant recipients, kidney cancer can develop in both the remaining native kidney and in the transplanted kidney [<a href="#rid75">75</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Kidney transplant recipients are at increased risk of developing carcinoma of the native kidneys, particularly if they have undergone prolonged periods of dialysis [<a href="#rid76">76,77</a>]. The incidence is approximately 100 times greater than expected [<a href="#rid78">78,79</a>]. Why this might occur is not known. It may be related in part to the factors that, during the period of advanced kidney failure, lead to tubular hyperplasia, cyst formation, and, in some cases, malignant transformation. (See  <a class="medical medical_review" href="/z/d/html/1683.html" rel="external">"Acquired cystic disease of the kidney in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Kidney tumors are rare in transplanted kidneys. A retrospective, multicenter study identified 20 patients with histologically confirmed tumors in a survey of 11 European centers [<a href="#rid80">80</a>]. Tumors were small (0.6 to 4 cm in diameter). Pathologically, 17 were papillary, and 3 were clear cell, in contrast to the predominance of clear cell tumors in other populations. All patients were successfully managed with either radiofrequency ablation or cryoablation and without a change in immunosuppression, although one patient developed a new tumor (clear cell carcinoma).</p><p></p><p>A number of options are available in the management of renal cell carcinoma (RCC) that emerges from a transplanted kidney [<a href="#rid75">75,81</a>]. In those without metastatic disease, total transplant nephrectomy may be curative, although a return to dialysis is required. Some have suggested that consideration may be given to nephron-sparing surgery in those with nonmetastatic RCC that is less than 4 cm in size and located peripherally [<a href="#rid77">77,82</a>]. This approach has been reported thus far in only a few cases [<a href="#rid82">82</a>]. Metastatic disease should be treated with cessation of immunosuppression, transplant nephrectomy, and immune therapy [<a href="#rid77">77</a>].</p><p class="headingAnchor" id="H2282764694"><span class="h1">CANCER SCREENING</span><span class="headingEndMark"> — </span>The ability to prevent and detect solid organ malignancies in the transplant patient, particularly early-stage cancers, relies upon periodic screening examinations and strict adherence to prophylactic measures. However, direct evidence to support specific screening practices in solid organ transplant recipients is lacking [<a href="#rid83">83</a>]. In general, we, and most transplant centers, perform age-appropriate cancer screening in solid organ transplant recipients that is similar to cancer screening recommended for the general population. For certain malignancies, such as skin cancer, liver cancer, cervical cancer, and anogenital cancers, more frequent screening than what is advised for the general population is suggested for solid organ transplant recipients. Screening recommendations for specific cancers are discussed in more detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening recommendations similar to those for the general population:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Breast cancer (see  <a class="medical medical_review" href="/z/d/html/7564.html" rel="external">"Screening for breast cancer: Strategies and recommendations"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lung cancer (see  <a class="medical medical_review" href="/z/d/html/7566.html" rel="external">"Screening for lung cancer"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prostate cancer (see  <a class="medical medical_review" href="/z/d/html/7567.html" rel="external">"Screening for prostate cancer"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Colon cancer (see  <a class="medical medical_review" href="/z/d/html/7565.html" rel="external">"Screening for colorectal cancer: Strategies in patients at average risk"</a> and  <a class="medical medical_review" href="/z/d/html/7572.html" rel="external">"Screening for colorectal cancer in patients with a family history of colorectal cancer or advanced polyp"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening recommendations tailored to solid organ transplant recipients:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Skin cancer (see  <a class="medical medical_review" href="/z/d/html/16339.html" rel="external">"Prevention and management of skin cancer in solid organ transplant recipients", section on 'Post-transplantation surveillance'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cervical cancer (see  <a class="medical medical_review" href="/z/d/html/3220.html" rel="external">"Screening for cervical cancer in patients with HIV infection and other immunocompromised states", section on 'Immunosuppressed patients without HIV'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Liver cancer (in liver transplant recipients) (see  <a class="medical medical_review" href="/z/d/html/2490.html" rel="external">"Liver transplantation for hepatocellular carcinoma", section on 'Post-transplantation surveillance'</a> and  <a class="medical medical_review" href="/z/d/html/4589.html" rel="external">"Liver transplantation in adults: Long-term management of transplant recipients", section on 'Screening and prevention'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Anal intraepithelial neoplasia (see  <a class="medical medical_review" href="/z/d/html/8032.html" rel="external">"Anal squamous intraepithelial lesions: Epidemiology, clinical presentation, diagnosis, screening, prevention, and treatment", section on 'Who should be screened for anal SIL?'</a>)</p><p></p><p class="headingAnchor" id="H3111147838"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H1910190906"><span class="h2">General preventive measures</span><span class="headingEndMark"> — </span>The approach to posttransplant malignancies begins with general preventive measures, which include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Careful screening of the patient and donor prior to transplantation to help detect an underlying preexisting malignancy. (See  <a class="medical medical_review" href="/z/d/html/7309.html" rel="external">"Kidney transplantation in adults: Evaluation of the potential kidney transplant recipient"</a> and  <a class="medical medical_review" href="/z/d/html/7315.html" rel="external">"Kidney transplantation in adults: Evaluation of the living kidney donor candidate", section on 'Malignancy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of excess immunosuppression, especially with calcineurin inhibitors (CNIs), or repeated exposure to agents that selectively target T lymphocytes such as antithymocyte globulin (ATG) or OKT3. (See <a class="local">'Immunosuppression'</a> above and  <a class="medical medical_review" href="/z/d/html/7335.html" rel="external">"Treatment and prevention of post-transplant lymphoproliferative disorders", section on 'Tapering immunosuppressive therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sun-protective measures, such as sun avoidance and regular use of sunscreens and sun-protective clothing. These and other issues related to the prevention of skin cancer among solid organ transplant recipients are discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16339.html" rel="external">"Prevention and management of skin cancer in solid organ transplant recipients", section on 'Prevention'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vaccination against human papillomavirus (HPV) for patients who have an age-based indication for HPV vaccination. (See <a class="local">'Coexisting viral infection'</a> above and  <a class="medical medical_review" href="/z/d/html/3892.html" rel="external">"Immunizations in solid organ transplant candidates and recipients", section on 'Human papillomavirus'</a> and  <a class="medical medical_review" href="/z/d/html/8325.html" rel="external">"Human papillomavirus vaccination", section on 'Indications and age range'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some centers administer antiviral prophylaxis with <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">acyclovir</a> or <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">valacyclovir</a> to solid organ transplant recipients who are seronegative for Epstein-Barr virus but who receive organs from seropositive donors. Supportive evidence for this practice as well as other issues related to the prevention of posttransplant lymphoproliferative disorder (PTLD) are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/7335.html" rel="external">"Treatment and prevention of post-transplant lymphoproliferative disorders", section on 'Antiviral prophylaxis'</a>.)</p><p></p><p class="headingAnchor" id="H3777727144"><span class="h2">Patients with a de novo cancer after transplant</span></p><p class="headingAnchor" id="H3826917269"><span class="h3">Reduction in immunosuppression</span><span class="headingEndMark"> — </span>Reduction or cessation of immunosuppressive therapy is useful primarily for patients who have undergone kidney transplantation since loss of the graft to rejection is not a fatal event in these patients. However, a reduction in immunosuppression may also be tolerated in heart, lung, or liver recipients. Such measures may result in tumor regression in some cases of lymphoma; some skin cancers; Kaposi sarcoma (KS), in which reducing the CNI exposure may be particularly important [<a href="#rid62">62,65,84,85</a>]; and donor-derived malignancies. (See  <a class="medical medical_review" href="/z/d/html/7335.html" rel="external">"Treatment and prevention of post-transplant lymphoproliferative disorders", section on 'Treatment'</a> and <a class="local">'Kaposi sarcoma'</a> above.)</p><p>For most solid organ transplant recipients with a de novo cancer after transplant, we suggest a reduction in immunosuppression rather than continuing standard immunosuppression. The optimal approach to reducing immunosuppression in this setting is uncertain, and strategies vary depending upon the cancer type and type of organ transplant. We take the following approach:</p><p class="bulletIndent1"><span class="glyph">●</span>For transplant recipients with a de novo cancer other than KS or PTLD, we suggest discontinuing the antimetabolite rather than discontinuing the CNI or switching from a CNI to a mammalian (mechanistic) target of rapamycin (mTOR) inhibitor. Despite the association of the CNIs with increased transforming growth factor-beta levels and the risk of malignancy, rejection is less likely to occur with double therapy with a CNI and <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> than the combination of an antimetabolite with prednisone. In addition, substituting mTOR inhibitor therapy in place of CNIs has fallen into disfavor for most cancers due to the adverse impact on overall survival [<a href="#rid31">31,86</a>]. (See <a class="local">'Immunosuppression'</a> above.)</p><p></p><p class="bulletIndent1">An exception to this approach is in very well-matched human leukocyte antigen (HLA) transplant recipients, such as 0-HLA or 0-B, 0-DR mismatched recipients, in whom the risk of rejection is low with the combination of an antimetabolite and <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>. In such patients, discontinuing the CNI, rather than the antimetabolite, may be reasonable. This combination also avoids the nephrotoxicity and malignancy potential associated with a CNI.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For transplant recipients with posttransplant KS, we suggest switching from a CNI to an mTOR inhibitor rather than discontinuing the antimetabolite. In such patients, switching from a CNI to an mTOR inhibitor has been associated with disease regression in one observational study [<a href="#rid27">27,63</a>]. Some experts switch from a CNI to an mTOR inhibitor in transplant recipients receiving checkpoint inhibitor immunotherapy, although there is no high-quality evidence to support this approach. (See <a class="local">'Immunosuppression'</a> above and <a class="local">'Avoidance of immune checkpoint inhibitors'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The reduction of immunosuppression in transplant recipients with PTLD is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7335.html" rel="external">"Treatment and prevention of post-transplant lymphoproliferative disorders", section on 'Reduction in immunosuppression'</a>.)</p><p></p><p>Data evaluating the efficacy and safety of reducing immunosuppression in transplant recipients with a de novo cancer are limited to mostly observational studies. These data are presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16339.html" rel="external">"Prevention and management of skin cancer in solid organ transplant recipients", section on 'Reduction of immunosuppressive therapy'</a> and  <a class="medical medical_review" href="/z/d/html/7335.html" rel="external">"Treatment and prevention of post-transplant lymphoproliferative disorders", section on 'Reduction in immunosuppression'</a>.)</p><p>If evaluation of the tumor reveals it to be of donor origin, reduction of immunosuppression may theoretically lead to rejection of the tumor. Although this has been effective in PTLD, there is little evidence that this is effective in other tumors [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H1621873215"><span class="h3">Avoidance of immune checkpoint inhibitors</span><span class="headingEndMark"> — </span>In general, solid organ transplant recipients with a de novo cancer after transplant can be managed with the same therapeutic approaches used to treat nontransplant patients with cancer, without concern that such therapies may lead to organ rejection or loss of the transplant. One exception, however, is the use of checkpoint inhibitor immunotherapy (ie, cytotoxic T-lymphocyte antigen 4 and programmed cell death 1 antibodies), which should be avoided, if possible, in solid organ transplant recipients due to the increased risk of organ rejection with this class of agents. If checkpoint inhibitors are used, adjustment of the maintenance immunosuppression regimen may be warranted, although the optimal approach to this is not known. Some experts prefer to use low-dose <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> (target trough level 3 to 5 ng/mL) and <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>; other experts favor switching to an mTOR inhibitor and prednisone. (See <a class="local">'Reduction in immunosuppression'</a> above.)</p><p>Several studies have shown that the use of immune checkpoint inhibitors in solid organ transplant recipients with cancer has been associated with an increased risk of rejection [<a href="#rid87">87-90</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a systematic review of case series and reports that included 64 solid organ transplant recipients (39 kidney, 19 liver, and 5 heart) treated with checkpoint inhibitors, the overall rate of graft rejection was 41 percent [<a href="#rid90">90</a>]. Graft rejection occurred in 44, 39, and 20 percent of kidney, liver, and heart transplant recipients, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a multicenter retrospective analysis of 69 kidney transplant recipients who received a checkpoint inhibitor (mostly for cutaneous squamous cell carcinoma and melanoma), 29 patients (42 percent) developed acute rejection and 19 lost their allograft [<a href="#rid88">88</a>]. By comparison, rejection occurred in only 5 percent of cancer stage-matched transplant recipients who were not treated with a checkpoint inhibitor.</p><p></p><p class="headingAnchor" id="H165446228"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110754.html" rel="external">"Society guideline links: Kidney transplantation"</a>.)</p><p class="headingAnchor" id="H4261921439"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology and risk factors </strong>– There is an increased risk of a wide range of cancers associated with solid organ transplantation. The incidence of specific malignancies appears to vary depending upon the organ transplanted. Several factors have been linked to the increased incidence of secondary malignancies among transplant recipients, including sun exposure; type, extent, and duration of immunosuppression; and concomitant viral infection. In rare cases, malignancy has been transplanted from the donor. (See <a class="local">'Incidence'</a> above and <a class="local">'Risk factors for malignancy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Common cancer types </strong>– Common cancer types among solid organ transplant recipients include skin cancers, Kaposi sarcoma (KS), lymphoproliferative disorders, anogenital cancers, lung cancer, liver cancer (in liver transplant recipients), and kidney cancer (in kidney transplant recipients). (See <a class="local">'Common cancer types in transplant recipients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cancer screening </strong>– The ability to prevent and detect solid organ malignancies in the transplant patient, particularly early-stage cancers, relies upon periodic screening examinations and strict adherence to prophylactic measures. However, direct evidence to support specific screening practices in this population is lacking. In general, we, and most transplant centers, perform age-appropriate cancer screening in solid organ transplant recipients that is similar to cancer screening recommended for the general population. For certain malignancies, such as skin cancer, liver cancer, cervical cancer, and anogenital cancers, more frequent screening than what is advised for the general population is suggested for solid organ transplant recipients. (See <a class="local">'Cancer screening'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Preventive measures </strong>– The approach to posttransplant malignancies begins with general preventive measures. In particular, excess immunosuppression or repeated exposure to antilymphocyte drugs should be avoided. Careful screening of the patient and donor prior to transplantation to help detect an underlying, preexisting malignancy should also be performed. (See <a class="local">'General preventive measures'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Reduction in immunosuppression </strong>– For most solid organ transplant recipients with a de novo cancer after transplant, we suggest a reduction in immunosuppression rather than continuing standard immunosuppression (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For transplant recipients with a de novo cancer other than KS or posttransplant lymphoproliferative disorder (PTLD), we suggest discontinuing the antimetabolite rather than discontinuing the calcineurin inhibitor (CNI) or switching from a CNI to a mammalian (mechanistic) target of rapamycin (mTOR) inhibitor (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For transplant recipients with posttransplant KS, we suggest switching from a CNI to an mTOR inhibitor rather than discontinuing the antimetabolite (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The management of immunosuppression among those with PTLD is presented separately. (See <a class="local">'Reduction in immunosuppression'</a> above and  <a class="medical medical_review" href="/z/d/html/7335.html" rel="external">"Treatment and prevention of post-transplant lymphoproliferative disorders", section on 'Reduction in immunosuppression'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other transplant-specific considerations </strong>– In general, transplant recipients with a de novo cancer after transplant can be managed with the same therapeutic approaches used to treat nontransplant patients with cancer, without concern that such therapies may lead to organ rejection or loss of the transplant. However, the use of checkpoint inhibitor immunotherapy should be avoided, if possible, due to the increased risk of organ rejection with this class of agents. (See <a class="local">'Avoidance of immune checkpoint inhibitors'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011; 306:1891.</a></li><li><a class="nounderline abstract_t">Asch WS, Bia MJ. Oncologic issues and kidney transplantation: a review of frequency, mortality, and screening. Adv Chronic Kidney Dis 2014; 21:106.</a></li><li><a class="nounderline abstract_t">Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370:59.</a></li><li><a class="nounderline abstract_t">Ramsey-Goldman R, Brar A, Richardson C, et al. Standardised incidence ratios (SIRs) for cancer after renal transplant in systemic lupus erythematosus (SLE) and non-SLE recipients. Lupus Sci Med 2016; 3:e000156.</a></li><li><a class="nounderline abstract_t">Hortlund M, Arroyo Mühr LS, Storm H, et al. Cancer risks after solid organ transplantation and after long-term dialysis. Int J Cancer 2017; 140:1091.</a></li><li><a class="nounderline abstract_t">Kitchlu A, Dixon S, Dirk JS, et al. Elevated Risk of Cancer After Solid Organ Transplant in Childhood: A Population-based Cohort Study. Transplantation 2019; 103:588.</a></li><li><a class="nounderline abstract_t">Safaeian M, Robbins HA, Berndt SI, et al. Risk of Colorectal Cancer After Solid Organ Transplantation in the United States. Am J Transplant 2016; 16:960.</a></li><li><a class="nounderline abstract_t">Laprise C, Cahoon EK, Lynch CF, et al. Risk of lip cancer after solid organ transplantation in the United States. Am J Transplant 2019; 19:227.</a></li><li><a class="nounderline abstract_t">Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005; 80:S254.</a></li><li><a class="nounderline abstract_t">Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342:1514.</a></li><li><a class="nounderline abstract_t">Caforio AL, Fortina AB, Piaserico S, et al. Skin cancer in heart transplant recipients: risk factor analysis and relevance of immunosuppressive therapy. Circulation 2000; 102:III222.</a></li><li><a class="nounderline abstract_t">Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351:623.</a></li><li><a class="nounderline abstract_t">Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397:530.</a></li><li><a class="nounderline abstract_t">Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8:128.</a></li><li><a class="nounderline abstract_t">Shihab FS, Bennett WM, Isaac J, et al. Nitric oxide modulates vascular endothelial growth factor and receptors in chronic cyclosporine nephrotoxicity. Kidney Int 2003; 63:522.</a></li><li><a class="nounderline abstract_t">Guba M, Graeb C, Jauch KW, Geissler EK. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 2004; 77:1777.</a></li><li><a class="nounderline abstract_t">Imao T, Ichimaru N, Takahara S, et al. Risk factors for malignancy in Japanese renal transplant recipients. Cancer 2007; 109:2109.</a></li><li><a class="nounderline abstract_t">Maluccio M, Sharma V, Lagman M, et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation 2003; 76:597.</a></li><li><a class="nounderline abstract_t">Swann PF, Waters TR, Moulton DC, et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 1996; 273:1109.</a></li><li><a class="nounderline abstract_t">Engl T, Makarević J, Relja B, et al. Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy. BMC Cancer 2005; 5:4.</a></li><li><a class="nounderline abstract_t">Robson R, Cecka JM, Opelz G, et al. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 2005; 5:2954.</a></li><li><a class="nounderline abstract_t">O'Neill JO, Edwards LB, Taylor DO. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25:1186.</a></li><li><a class="nounderline abstract_t">Luan FL, Ding R, Sharma VK, et al. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 2003; 63:917.</a></li><li><a class="nounderline abstract_t">Huber S, Bruns CJ, Schmid G, et al. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int 2007; 71:771.</a></li><li><a class="nounderline abstract_t">Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17:581.</a></li><li><a class="nounderline abstract_t">Luan FL, Hojo M, Maluccio M, et al. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002; 73:1565.</a></li><li><a class="nounderline abstract_t">Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 2004; 77:760.</a></li><li><a class="nounderline abstract_t">Euvrard S, Ulrich C, Lefrancois N. Immunosuppressants and skin cancer in transplant patients: focus on rapamycin. Dermatol Surg 2004; 30:628.</a></li><li><a class="nounderline abstract_t">Kahan BD, Yakupoglu YK, Schoenberg L, et al. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 2005; 80:749.</a></li><li><a class="nounderline abstract_t">Knoll GA, Kokolo MB, Mallick R, et al. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ 2014; 349:g6679.</a></li><li><a class="nounderline abstract_t">Yanik EL, Siddiqui K, Engels EA. Sirolimus effects on cancer incidence after kidney transplantation: a meta-analysis. Cancer Med 2015; 4:1448.</a></li><li><a class="nounderline abstract_t">Yanik EL, Gustafson SK, Kasiske BL, et al. Sirolimus use and cancer incidence among US kidney transplant recipients. Am J Transplant 2015; 15:129.</a></li><li><a class="nounderline abstract_t">Miller G, Rigsby MO, Heston L, et al. Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection. N Engl J Med 1996; 334:1292.</a></li><li><a class="nounderline abstract_t">Munoz P, Alvarez P, de Ory F, et al. Incidence and clinical characteristics of Kaposi sarcoma after solid organ transplantation in Spain: importance of seroconversion against HHV-8. Medicine (Baltimore) 2002; 81:293.</a></li><li><a class="nounderline abstract_t">Qunibi W, Al-Furayh O, Almeshari K, et al. Serologic association of human herpesvirus eight with posttransplant Kaposi's sarcoma in Saudi Arabia. Transplantation 1998; 65:583.</a></li><li><a class="nounderline abstract_t">Francès C, Mouquet C, Marcelin AG, et al. Outcome of kidney transplant recipients with previous human herpesvirus-8 infection. Transplantation 2000; 69:1776.</a></li><li><a class="nounderline abstract_t">Ramsay HM, Fryer AA, Hawley CM, et al. Factors associated with nonmelanoma skin cancer following renal transplantation in Queensland, Australia. J Am Acad Dermatol 2003; 49:397.</a></li><li><a class="nounderline abstract_t">Regamey N, Tamm M, Wernli M, et al. Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients. N Engl J Med 1998; 339:1358.</a></li><li><a class="nounderline abstract_t">Barozzi P, Luppi M, Facchetti F, et al. Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors. Nat Med 2003; 9:554.</a></li><li><a class="nounderline abstract_t">Emond JP, Marcelin AG, Dorent R, et al. Kaposi's sarcoma associated with previous human herpesvirus 8 infection in heart transplant recipients. J Clin Microbiol 2002; 40:2217.</a></li><li><a class="nounderline abstract_t">Razonable RR. Human herpesviruses 6, 7 and 8 in solid organ transplant recipients. Am J Transplant 2013; 13 Suppl 3:67.</a></li><li><a class="nounderline abstract_t">Penn I. Malignant melanoma in organ allograft recipients. Transplantation 1996; 61:274.</a></li><li><a class="nounderline abstract_t">Myron Kauffman H, McBride MA, Cherikh WS, et al. Transplant tumor registry: donor related malignancies. Transplantation 2002; 74:358.</a></li><li><a class="nounderline abstract_t">Birkeland SA, Storm HH. Risk for tumor and other disease transmission by transplantation: a population-based study of unrecognized malignancies and other diseases in organ donors. Transplantation 2002; 74:1409.</a></li><li><a class="nounderline abstract_t">Pedotti P, Poli F, Longhi E, et al. Epidemiologic study on the origin of cancer after kidney transplantation. Transplantation 2004; 77:426.</a></li><li><a class="nounderline abstract_t">Armanios MY, Grossman SA, Yang SC, et al. Transmission of glioblastoma multiforme following bilateral lung transplantation from an affected donor: case study and review of the literature. Neuro Oncol 2004; 6:259.</a></li><li><a class="nounderline abstract_t">Penn I. Donor transmitted disease: cancer. Transplant Proc 1991; 23:2629.</a></li><li><a class="nounderline abstract_t">Buell JF, Trofe J, Hanaway MJ, et al. Transmission of donor cancer into cardiothoracic transplant recipients. Surgery 2001; 130:660.</a></li><li><a class="nounderline abstract_t">Kauffman HM, McBride MA, Delmonico FL. First report of the United Network for Organ Sharing Transplant Tumor Registry: donors with a history of cancer. Transplantation 2000; 70:1747.</a></li><li><a class="nounderline abstract_t">Wang JH, Pfeiffer RM, Musgrove D, et al. Cancer Mortality Among Solid Organ Transplant Recipients in the United States During 1987-2018. Transplantation 2023; 107:2433.</a></li><li><a class="nounderline abstract_t">Acuna SA, Fernandes KA, Daly C, et al. Cancer Mortality Among Recipients of Solid-Organ Transplantation in Ontario, Canada. JAMA Oncol 2016; 2:463.</a></li><li><a class="nounderline abstract_t">Friman TK, Jäämaa-Holmberg S, Åberg F, et al. Cancer risk and mortality after solid organ transplantation: A population-based 30-year cohort study in Finland. Int J Cancer 2022; 150:1779.</a></li><li><a class="nounderline abstract_t">Au EH, Chapman JR, Craig JC, et al. Overall and Site-Specific Cancer Mortality in Patients on Dialysis and after Kidney Transplant. J Am Soc Nephrol 2019; 30:471.</a></li><li><a class="nounderline abstract_t">Moosa MR. Racial and ethnic variations in incidence and pattern of malignancies after kidney transplantation. Medicine (Baltimore) 2005; 84:12.</a></li><li><a class="nounderline abstract_t">Iscovich J, Boffetta P, Winkelmann R, et al. Classic Kaposi's sarcoma in Jews living in Israel, 1961-1989: a population-based incidence study. AIDS 1998; 12:2067.</a></li><li><a class="nounderline abstract_t">Fenig E, Brenner B, Rakowsky E, et al. Classic Kaposi sarcoma: experience at Rabin Medical Center in Israel. Am J Clin Oncol 1998; 21:498.</a></li><li><a class="nounderline abstract_t">Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348:1681.</a></li><li><a class="nounderline abstract_t">Farge D. Kaposi's sarcoma in organ transplant recipients. The Collaborative Transplantation Research Group of Ile de France. Eur J Med 1993; 2:339.</a></li><li><a class="nounderline abstract_t">Moosa MR. Kaposi's sarcoma in kidney transplant recipients: a 23-year experience. QJM 2005; 98:205.</a></li><li><a class="nounderline abstract_t">Aseni P, Vertemati M, Minola E, et al. Kaposi's sarcoma in liver transplant recipients: morphological and clinical description. Liver Transpl 2001; 7:816.</a></li><li><a class="nounderline abstract_t">Penn I. Sarcomas in organ allograft recipients. Transplantation 1995; 60:1485.</a></li><li><a class="nounderline abstract_t">Francès C. Kaposi's sarcoma after renal transplantation. Nephrol Dial Transplant 1998; 13:2768.</a></li><li><a class="nounderline abstract_t">Dantal J, Soulillou JP. Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med 2005; 352:1371.</a></li><li><a class="nounderline abstract_t">Adami J, Gäbel H, Lindelöf B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003; 89:1221.</a></li><li><a class="nounderline abstract_t">Penn I. Cancers complicating organ transplantation. N Engl J Med 1990; 323:1767.</a></li><li><a class="nounderline abstract_t">Penn I. Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases. Cancer 1986; 58:611.</a></li><li><a class="nounderline abstract_t">Penn I. De novo malignances in pediatric organ transplant recipients. Pediatr Transplant 1998; 2:56.</a></li><li><a class="nounderline abstract_t">Euvrard S, Kanitakis J, Chardonnet Y, et al. External anogenital lesions in organ transplant recipients. A clinicopathologic and virologic assessment. Arch Dermatol 1997; 133:175.</a></li><li><a class="nounderline abstract_t">Anyanwu AC, Townsend ER, Banner NR, et al. Primary lung carcinoma after heart or lung transplantation: management and outcome. J Thorac Cardiovasc Surg 2002; 124:1190.</a></li><li><a class="nounderline abstract_t">Rinaldi M, Pellegrini C, D'Armini AM, et al. Neoplastic disease after heart transplantation: single center experience. Eur J Cardiothorac Surg 2001; 19:696.</a></li><li><a class="nounderline abstract_t">Goldstein DJ, Austin JH, Zuech N, et al. Carcinoma of the lung after heart transplantation. Transplantation 1996; 62:772.</a></li><li><a class="nounderline abstract_t">Minai OA, Shah S, Mazzone P, et al. Bronchogenic carcinoma after lung transplantation: characteristics and outcomes. J Thorac Oncol 2008; 3:1404.</a></li><li><a class="nounderline abstract_t">Génébès C, Brouchet L, Kamar N, et al. Characteristics of thoracic malignancies that occur after solid-organ transplantation. J Thorac Oncol 2010; 5:1789.</a></li><li><a class="nounderline abstract_t">Arcasoy SM. Controversies in bronchogenic carcinoma following lung transplantation: type of transplant operation and role of screening. J Thorac Oncol 2008; 3:1377.</a></li><li><a class="nounderline abstract_t">Dahle DO, Skauby M, Langberg CW, et al. Renal Cell Carcinoma and Kidney Transplantation: A Narrative Review. Transplantation 2022; 106:e52.</a></li><li><a class="nounderline abstract_t">Hiesse C, Rieu P, Kriaa F, et al. Malignancy after renal transplantation: analysis of incidence and risk factors in 1700 patients followed during a 25-year period. Transplant Proc 1997; 29:831.</a></li><li><a class="nounderline abstract_t">Muruve NA, Shoskes DA. Genitourinary malignancies in solid organ transplant recipients. Transplantation 2005; 80:709.</a></li><li><a class="nounderline abstract_t">Doublet JD, Peraldi MN, Gattegno B, et al. Renal cell carcinoma of native kidneys: prospective study of 129 renal transplant patients. J Urol 1997; 158:42.</a></li><li><a class="nounderline abstract_t">Denton MD, Magee CC, Ovuworie C, et al. Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: a pathologic analysis. Kidney Int 2002; 61:2201.</a></li><li><a class="nounderline abstract_t">Cornelis F, Buy X, André M, et al. De novo renal tumors arising in kidney transplants: midterm outcome after percutaneous thermal ablation. Radiology 2011; 260:900.</a></li><li><a class="nounderline abstract_t">Leibovich BC, Blute M, Cheville JC, et al. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol 2004; 171:1066.</a></li><li><a class="nounderline abstract_t">Moudouni SM, Tligui M, Doublet JD, et al. Nephron-sparing surgery for de novo renal cell carcinoma in allograft kidneys. Transplantation 2005; 80:865.</a></li><li><a class="nounderline abstract_t">Acuna SA, Huang JW, Scott AL, et al. Cancer Screening Recommendations for Solid Organ Transplant Recipients: A Systematic Review of Clinical Practice Guidelines. Am J Transplant 2017; 17:103.</a></li><li class="breakAll">Penn I. Why do immunosuppressed patients develop cancer?. In: CRC Critical Reviews in Oncogenesis, Pimentel E (Ed), CRC, Boca Raton 1989. p.27.</li><li><a class="nounderline abstract_t">Duman S, Töz H, Aşçi G, et al. Successful treatment of post-transplant Kaposi's sarcoma by reduction of immunosuppression. Nephrol Dial Transplant 2002; 17:892.</a></li><li><a class="nounderline abstract_t">Hellemans R, Pengel LHM, Choquet S, et al. Managing immunosuppressive therapy in potentially cured post-kidney transplant cancer (excluding non-melanoma skin cancer): an overview of the available evidence and guidance for shared decision-making. Transpl Int 2021; 34:1789.</a></li><li><a class="nounderline abstract_t">Fisher J, Zeitouni N, Fan W, Samie FH. Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review. J Am Acad Dermatol 2020; 82:1490.</a></li><li><a class="nounderline abstract_t">Murakami N, Mulvaney P, Danesh M, et al. A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney Int 2021; 100:196.</a></li><li><a class="nounderline abstract_t">Manohar S, Thongprayoon C, Cheungpasitporn W, et al. Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients. Kidney Int Rep 2020; 5:149.</a></li><li><a class="nounderline abstract_t">Kumar V, Shinagare AB, Rennke HG, et al. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature. Oncologist 2020; 25:505.</a></li></ol></div><div id="topicVersionRevision">Topic 7304 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22045767" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Spectrum of cancer risk among US solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24359993" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Oncologic issues and kidney transplantation: a review of frequency, mortality, and screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17617273" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27335659" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Standardised incidence ratios (SIRs) for cancer after renal transplant in systemic lupus erythematosus (SLE) and non-SLE recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27870055" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cancer risks after solid organ transplantation and after long-term dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30048393" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Elevated Risk of Cancer After Solid Organ Transplant in Childhood: A Population-based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26731613" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Risk of Colorectal Cancer After Solid Organ Transplantation in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30074684" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Risk of lip cancer after solid organ transplantation in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16251858" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Malignancy after transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7902900" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11082391" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Skin cancer in heart transplant recipients: risk factor analysis and relevance of immunosuppressive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9500317" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10028970" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Cyclosporine induces cancer progression by a cell-autonomous mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11821896" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12631117" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Nitric oxide modulates vascular endothelial growth factor and receptors in chronic cyclosporine nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15223891" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17407138" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Risk factors for malignancy in Japanese renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12923450" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8688098" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15644133" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16303010" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17045930" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12631072" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Rapamycin is an effective inhibitor of human renal cancer metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17299523" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16434506" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12042641" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15021843" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15061847" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Immunosuppressants and skin cancer in transplant patients: focus on rapamycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16210961" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25422259" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26108799" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Sirolimus effects on cancer incidence after kidney transplantation: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25522018" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Sirolimus use and cancer incidence among US kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8609946" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12169884" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Incidence and clinical characteristics of Kaposi sarcoma after solid organ transplantation in Spain: importance of seroconversion against HHV-8.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9500639" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Serologic association of human herpesvirus eight with posttransplant Kaposi's sarcoma in Saudi Arabia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10830210" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Outcome of kidney transplant recipients with previous human herpesvirus-8 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12963901" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Factors associated with nonmelanoma skin cancer following renal transplantation in Queensland, Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9801396" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12692543" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12037090" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Kaposi's sarcoma associated with previous human herpesvirus 8 infection in heart transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23347215" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Human herpesviruses 6, 7 and 8 in solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8600636" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Malignant melanoma in organ allograft recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12177614" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Transplant tumor registry: donor related malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12451241" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Risk for tumor and other disease transmission by transplantation: a population-based study of unrecognized malignancies and other diseases in organ donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14966419" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Epidemiologic study on the origin of cancer after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15279719" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Transmission of glioblastoma multiforme following bilateral lung transplantation from an affected donor: case study and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1926512" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Donor transmitted disease: cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11602897" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Transmission of donor cancer into cardiothoracic transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11152107" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : First report of the United Network for Organ Sharing Transplant Tumor Registry: donors with a history of cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37291711" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Cancer Mortality Among Solid Organ Transplant Recipients in the United States During 1987-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26746479" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Cancer Mortality Among Recipients of Solid-Organ Transplantation in Ontario, Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35041762" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Cancer risk and mortality after solid organ transplantation: A population-based 30-year cohort study in Finland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30765426" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Overall and Site-Specific Cancer Mortality in Patients on Dialysis and after Kidney Transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15643296" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Racial and ethnic variations in incidence and pattern of malignancies after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9814876" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Classic Kaposi's sarcoma in Jews living in Israel, 1961-1989: a population-based incidence study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9781608" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Classic Kaposi sarcoma: experience at Rabin Medical Center in Israel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12711744" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Skin cancers after organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8252179" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Kaposi's sarcoma in organ transplant recipients. The Collaborative Transplantation Research Group of Ile de France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15728402" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Kaposi's sarcoma in kidney transplant recipients: a 23-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11552218" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Kaposi's sarcoma in liver transplant recipients: morphological and clinical description.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8545879" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Sarcomas in organ allograft recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9829477" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Kaposi's sarcoma after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15800234" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Immunosuppressive drugs and the risk of cancer after organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14520450" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Cancer risk following organ transplantation: a nationwide cohort study in Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2247108" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Cancers complicating organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3524788" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10084762" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : De novo malignances in pediatric organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9041830" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : External anogenital lesions in organ transplant recipients. A clinicopathologic and virologic assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12447186" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Primary lung carcinoma after heart or lung transplantation: management and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11343955" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Neoplastic disease after heart transplantation: single center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8824476" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Carcinoma of the lung after heart transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19057264" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Bronchogenic carcinoma after lung transplantation: characteristics and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20975378" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Characteristics of thoracic malignancies that occur after solid-organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19057259" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Controversies in bronchogenic carcinoma following lung transplantation: type of transplant operation and role of screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33741842" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Renal Cell Carcinoma and Kidney Transplantation: A Narrative Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9123545" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Malignancy after renal transplantation: analysis of incidence and risk factors in 1700 patients followed during a 25-year period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16210955" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Genitourinary malignancies in solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9186319" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Renal cell carcinoma of native kidneys: prospective study of 129 renal transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12028461" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: a pathologic analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21771957" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : De novo renal tumors arising in kidney transplants: midterm outcome after percutaneous thermal ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14767272" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16210977" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Nephron-sparing surgery for de novo renal cell carcinoma in allograft kidneys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27575845" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Cancer Screening Recommendations for Solid Organ Transplant Recipients: A Systematic Review of Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27575845" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Cancer Screening Recommendations for Solid Organ Transplant Recipients: A Systematic Review of Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11981080" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Successful treatment of post-transplant Kaposi's sarcoma by reduction of immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34146426" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Managing immunosuppressive therapy in potentially cured post-kidney transplant cancer (excluding non-melanoma skin cancer): an overview of the available evidence and guidance for shared decision-making.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31302190" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33359528" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32043028" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32043699" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
